We expect Stockwik to present a decent Q4 report on 17 February, and forecast EBITA of SEK 26m still...
Q4 report due on Tuesday, 21 February Raised opex and financial cost estimates We expect Germany at ...
Weaker-than-expected Q4 due to cancelled large customer FY'23 guidance places ABGSCe at the low end ...
We expect continued headwinds in Q4 '23e EBIT estimate down 3% on lower utilisation New fair value r...
Rekordstarkt 2022, men tecken på avmattning Nettoomsättningen ökade med 22% till 730 mkr i Q4 y/y, v...
Ingen påverkan på efterfrågan för slutkunderna Även om den organiska tillväxten är fortsatt negativ ...
Sales -4%, EBIT -27% vs. ABGSCe, 33% org sales (ABG 49%) Q1 guidance of ~40% growth y-o-y, but negat...
Q4 numbers broadly in line Soft guidance for '23 and low RRR Positive new on Block 58 and DPS of SEK...
EBIT SEK 66m (-9% vs. ABGSCe SEK 72m) Q4 numbers imply EBIT downgrades of 2% Trading at 12x '23e EV/...
Redeye’s first view on the Q4 report this morning. Cellavision clearly continues to see challenges e...
Q4 estimates nearly unchanged We cut '23e-'24e EBIT by 3-2% 8x '23e EV/EBIT What to look for in Q4'...
Q4’22e EBIT of SEK 132m, Inv. mgmt the main earnings driver Estimates only tweaked ahead of Q4'22e 2...
Redeye argues that the H2 report from Zwipe was largely in line with our expectations.
Redeye provides an update on Thunderful Group ahead of its Q4 2022 report, due on February 22.
Q4 prelim. revenue 2% below ABGSCe, EBIT 3% below '23e guidance entails 3-8% revenue decline.
Ett svagt Q4, men bolagets strategi mot mer förädlade produkter ger stabilitet Bergs rapporterade et...
Suominen’s Q4 figures remained below estimates; volumes and margins will rebound this year, but valu...
Consti’s Q4 results were strong as both revenue and profitability figures exceeded our estimates.
Redeye uppdaterar sin syn på BioArctic med anledning av Q4-rapporten och ytterligare framsteg för Le...
Baserat på forskning från Göteborg och Örebro universitet har det Göteborgsbaserade investmentbolage...
